Building in the most skeptical industry

Most industries will forgive a little theater if the product eventually works. Life science rarely grants that courtesy, because the people who buy, partner, fund, and critique the work are trained to treat every claim as provisional until the evidence holds. I build in that climate on purpose, and the cost of entry is simple to state even when it is hard to pay. You earn the right to sell only after you survive the scrutiny.

That scrutiny is older than any contemporary sales playbook. The scientific ethos itself treats skepticism as an institutional mandate, a temporary suspension of judgment paired with detached examination of belief against empirical and logical criteria (Merton, 1942/1973). In that frame, doubt is professional posture. A deck that asks a room to skip the examination asks the room to violate its own identity, and identity is a stubborn substance to market against.

Cognitive science sharpens the same point from another angle. Human communication is useful only if receivers can protect themselves from accidental and intentional misinformation, so minds run a suite of checks that calibrate trust to a source's competence and benevolence while testing new claims against prior belief (Sperber et al., 2010). Across domains often cited as proof of mass gullibility, from advertising to political messaging, influence turns out to be weaker than the folklore of persuasion suggests, especially when acceptance would force costly action (Mercier, 2017). Life-science buying is costly action by design. Capital, time, and scientific reputation move together, which means epistemic vigilance arrives already awake.

Reasoning itself tends toward an argumentative function, devising and evaluating arguments under social pressure in rooms where persuasion and critique share the same air (Mercier & Sperber, 2011). Inside a scientific culture, that reward structure gets amplified. Colleagues are practiced at generating counterarguments, at hunting weak links, and at asking which control was missing. A pitch that cannot survive that social audit fails for a deeper reason than poor storytelling. It fails the cognitive job the room is built to perform.

Industry practice maps onto that psychology with uncomfortable precision. Curiosity opens the door, then skepticism arrives to audit whatever walked through it, and the two rarely take turns for long (Ghanadan, 2012). Ordinary marketing funnels assume awareness can be pushed into desire on a schedule. That sequence breaks when the audience treats indifference and incomplete proof as rational defaults, and when a polished feature list reads as a request to lower standards while the room is still hunting for a reason to raise attention.

What actually moves a scientific buyer looks more like a research program than a campaign. Need has to be recognized before options are explored, and exploration has to mature before a specific solution is evaluated with any seriousness (Ghanadan, 2012). Skip a stage and the room does not get convinced. It gets quieter. The elaboration literature predicts a related geometry. When an issue carries high personal relevance, attitudes bend toward argument quality, while peripheral cues such as status theater carry less weight (Petty, Cacioppo & Goldman, 1981). For a scientist evaluating a tool that could warp an assay, a trial, or a career, relevance is already high. The argument either holds under method-level pressure or it does not.

There is a harder edge still. People often apply stricter decision criteria to conclusions they would rather reject, and looser criteria to conclusions they prefer, a pattern of motivated skepticism that shows up in both laboratory and political settings (Ditto & Lopez, 1992; Taber & Lodge, 2006). In life science that asymmetry becomes operational. Your preferred story about a product meets an audience trained to prefer stories that have already survived peer scrutiny. Congruent claims travel, whilst incongruent claims get counterargued. Source credibility, built from perceived expertise and trustworthiness, can help persuasion across decades of evidence, yet it remains fragile once trustworthiness cracks (Pornpitakpan, 2004). Hyperbole is one of the fastest ways to crack it, because the audience hears exaggeration as a signal that the speaker is optimizing for assent while the methods still demand truth.

I feel that sentiment every week as someone who still carries lab training into company-building. The scientist in me distrusts easy summaries. The builder in me still needs dates, customers, and capital. Holding both means treating persuasion as an extension of scientific integrity that has to remain answerable after the slide deck closes. If the claim cannot survive a skeptical colleague, it does not belong in the deck.

That is why I keep returning to this industry even when softer markets look easier. The skepticism is the point. Organized doubt forces the work to stay answerable, and it forces the company to stay answerable with it. Build for an audience that lives between curiosity and vigilance, and the scoreboard changes. Peer-checkable evidence, honest limits, and language that can survive a methods question become cheaper than performance, and performance that cannot cite its evidence stops getting a seat at the table.